Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.

Atropine 0.05% trumps 0.01% concentration in slowing myopia progression

28 Jun 2020

Atropine 0.05% has double the efficacy of 0.01% eye drops over 2 years, and the former remains the optimal concentration among atropine concentrations in slowing the progression of myopia, a recent study has shown.

Of the 438 children originally randomized to receive 0.05%, 0.025%, 0.01%, or placebo once daily in both eyes in the Low-Concentration Atropine for Myopia Progression (LAMP) phase I study, 383 (87 percent; aged 4-12 years) with myopia of at least –1.0 dioptre (D) were selected to continue in the extended trial (phase II).

Children in the placebo group (LAMP phase I) were switched to receive 0.05% atropine from the beginning of the second-year follow-up. Those in the 0.05%, 0.025%, and 0.01% atropine groups remained in the same regimen. The investigators measured cycloplegic refraction, axial length (AL), accommodation amplitude, photopic and mesopic pupil diameter, and best-corrected visual acuity at 4-month intervals.

The mean spherical equivalent (SE) over the 2-year period was 0.55±0.86 D in the 0.05% (p=0.015), 0.85±0.73 D in the 0.025% (p<0.001), and 1.12±0.85 D in the 0.01% atropine groups (p=0.02), with mean AL changes of 0.39±0.35 mm (p=0.04), 0.50±0.33 mm (p<0.001), and 0.59±0.38 mm (p=0.10), respectively, over 2 years.

Compared with year 1, the efficacy of 0.05% and 0.025% atropine at year 2 remained similar (p>0.1), while that in the 0.01% concentration improved slightly (p=0.04).

Switching to 0.05% atropine significantly reduced myopia progression for the phase I placebo group (SE change, 0.18 D in year 2 vs 0.82 D in year 1; p<0.001; AL elongated 0.15 mm in year 2 vs 0.43 mm in year 1; p<0.001).

“Accommodation loss and change in pupil size in all concentrations remained similar to the first-year results and were well tolerated,” the investigators noted. “Visual acuity and vision-related quality of life remained unaffected.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.